Public Employees Retirement System of Ohio Sells 1,705 Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT)

Public Employees Retirement System of Ohio trimmed its stake in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 4.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,885 shares of the biotechnology company’s stock after selling 1,705 shares during the quarter. Public Employees Retirement System of Ohio owned approximately 0.05% of Sarepta Therapeutics worth $5,757,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. BNP Paribas Arbitrage SA boosted its position in shares of Sarepta Therapeutics by 3.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,676 shares of the biotechnology company’s stock worth $319,000 after purchasing an additional 98 shares during the period. Janney Montgomery Scott LLC raised its holdings in Sarepta Therapeutics by 2.7% in the second quarter. Janney Montgomery Scott LLC now owns 4,078 shares of the biotechnology company’s stock valued at $620,000 after acquiring an additional 109 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in Sarepta Therapeutics by 10.4% in the second quarter. Nisa Investment Advisors LLC now owns 1,325 shares of the biotechnology company’s stock valued at $201,000 after acquiring an additional 125 shares in the last quarter. World Asset Management Inc raised its holdings in Sarepta Therapeutics by 6.1% in the second quarter. World Asset Management Inc now owns 2,312 shares of the biotechnology company’s stock valued at $351,000 after acquiring an additional 132 shares in the last quarter. Finally, BB&T Corp raised its holdings in Sarepta Therapeutics by 3.4% in the second quarter. BB&T Corp now owns 4,405 shares of the biotechnology company’s stock valued at $669,000 after acquiring an additional 143 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

In other Sarepta Therapeutics news, Director Michael W. Bonney acquired 2,000 shares of Sarepta Therapeutics stock in a transaction dated Monday, September 9th. The stock was bought at an average price of $86.74 per share, for a total transaction of $173,480.00. Following the transaction, the director now owns 7,051 shares in the company, valued at approximately $611,603.74. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Richard Barry acquired 1,300 shares of Sarepta Therapeutics stock in a transaction dated Monday, August 12th. The shares were acquired at an average price of $122.50 per share, with a total value of $159,250.00. Following the transaction, the director now owns 3,173,365 shares in the company, valued at approximately $388,737,212.50. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 30,752 shares of company stock valued at $3,502,664. Insiders own 6.60% of the company’s stock.



Several analysts recently issued reports on the stock. Needham & Company LLC cut their price target on shares of Sarepta Therapeutics from $196.00 to $170.00 and set a “buy” rating on the stock in a report on Wednesday, August 21st. Citigroup dropped their target price on shares of Sarepta Therapeutics from $201.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday, May 16th. Piper Jaffray Companies dropped their target price on shares of Sarepta Therapeutics from $208.00 to $185.00 and set an “overweight” rating on the stock in a report on Tuesday, August 20th. Royal Bank of Canada dropped their target price on shares of Sarepta Therapeutics to $204.00 and set an “outperform” rating on the stock in a report on Tuesday, August 20th. Finally, Cantor Fitzgerald dropped their target price on shares of Sarepta Therapeutics from $231.00 to $175.00 and set an “overweight” rating on the stock in a report on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the stock. Sarepta Therapeutics presently has an average rating of “Buy” and a consensus target price of $197.78.

SRPT traded down $0.86 on Thursday, reaching $88.22. The company had a trading volume of 56,632 shares, compared to its average volume of 1,371,020. The company has a fifty day moving average of $115.87 and a 200-day moving average of $125.74. The company has a market capitalization of $6.58 billion, a P/E ratio of -16.13 and a beta of 2.19. The company has a current ratio of 8.81, a quick ratio of 7.84 and a debt-to-equity ratio of 0.44. Sarepta Therapeutics Inc has a one year low of $83.62 and a one year high of $165.87.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported ($3.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.08) by ($2.66). Sarepta Therapeutics had a negative net margin of 165.52% and a negative return on equity of 55.37%. The company had revenue of $94.67 million during the quarter, compared to the consensus estimate of $91.05 million. During the same quarter in the prior year, the company earned ($1.67) EPS. The business’s quarterly revenue was up 28.8% on a year-over-year basis. Research analysts predict that Sarepta Therapeutics Inc will post -4.94 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Featured Article: How do CD ladders protect against rising interest rates?

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.